Measuring antibiotic levels in the lungs of people with COPD or cystic fibrosis
Compares ways of measuring lung antibiotic levels in COPD and cystic fibrosis.
Key facts
- Who runs it
- Medical University Of Vienna
- Where
- Vienna, AustriaSee the site
- Registry title
- Pulmonary pharmacokinetics of piperacillin/tazobactam and levofloxacin in patients with chronic obstructive pulmonary disease or cystic fibrosis: Comparison of epithelial lining fluid, in-vivo microdialysis and tissue biopsy. An exploratory pharmacokinetic study.
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 18 people, planned
- Started
- 11 Dec 2024
- Planned end
- 31 Dec 2025
- Type of study
- Interventional
- Record updated
- 11 December 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with COPD or cystic fibrosis who are planned to have a lung transplant on both sides. It compares three ways to measure antibiotic levels in the lung.
- Age
- Older than 18 and younger than 90 years.
- Sex
- Men and women can join.
- Disease stage
- COPD or cystic fibrosis, with a planned lung transplant on both sides (bilateral).
- Earlier treatment
- People who already had a lung transplant cannot join.
Main reasons for not taking part
- Cannot give informed consent
- Known allergy to the study drugs
- Prior lung transplantation
- Kidney failure before surgery, or chronic severe kidney problems including haemodialysis
- Chronic severe liver disease or ECLS bridging
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Written informed consent
- Planned bilateral lung transplantation
- Diagnosis of COPD or CF
- Age: > 18 and < 90 years
Who cannot take part
- Prior lung transplantation
- Known allergy to study drugs
- Preoperative renal failure
- Chronic severe renal insufficiency including haemodialysis
- Chronic severe liver disease
- Inability to give informed consent
- ECLS bridging
Where in Austria
- Medical University of ViennaVienna, AustriaTaking people
About the trial
What the trial wants to find out
The primary objective is the head-to-head comparison of three methods for measuring pulmonary antibiotic pharmacokinetics. Epithelial lining fluid concentrations at 75', tissue biopsy concentrations at 75' and in-vivo microdialysis concentrations during the 60-90' interval will be compared.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Pulmonary pharmacokinetics of piperacillin/tazobactam and levofloxacin in patients with chronic obstructive pulmonary disease or cystic fibrosis: Comparison of epithelial lining fluid, in-vivo microdialysis and tissue biopsy. An exploratory pharmacokinetic study.
- Plain-language title
- Measuring antibiotic levels in the lungs of people with COPD or cystic fibrosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 11 December 2024